Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST Harbouring KIT Exon 9 Mutations By Ogkologos - March 10, 2026 54 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an international retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR Lack of Benefit of Adding Immune Checkpoint Inhibitors to Chemotherapy in... December 6, 2021 Research with integrity – all the fun of the FAIR August 8, 2023 GENIE Registry Identifies Cancer Types Enriched with KRASG12C Somatic Mutations January 18, 2021 EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan July 13, 2023 Load more HOT NEWS ESMO World Congress on Gastrointestinal Cancer 2022 Barcelona, Spain 29 June... Her Cancer Surgery Was Postponed Due To The COVID-19 Pandemic —... EMA Recommends Extension of Indications for Venetoclax EMA Recommends Extension of Indications for Atezolizumab
